Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
Media ReleaseCopenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small...